Collismycin C reduces HMGB1-mediated septic responses and improves survival rate in septic mice. Issue 1 (2nd January 2021)

• Record Type: Journal Article
• Authors: Kim, Eonmi; Ku, Sae-Kwang; Yang, Sumin; Lee, Bong-Seon; Kim, Geum Jin; Choi, Hyukjae; Bae, Jong-Sup
• Is Part Of: Journal of Asian natural products research. Volume 23:Issue 1(2021)
• Page Start: 55
• Page End: 72
• Publication Date: 2021-01-02
• Subjects: Collismycin C -- endothelium -- HMGB1 -- sepsis; Materia medica -- Asia -- Periodicals; Pharmacognosy -- Asia -- Periodicals; Medicinal plants -- Asia -- Periodicals; Medicine, Oriental -- Asia -- Periodicals; 615.321095
• DOI: 10.1080/10286020.2019.1706497
• Languages: English
• ISSNs: 1028-6020

Abstract

Abstract: We examined the effects of a 2, 2′-bipyridine containing natural product, collismycin C on high mobility group box 1 (HMGB1, septic mediator)-mediated septic responses and survival rate in a mouse sepsis model. Collismycin C inhibited the HMGB1 release and downregulated HMGB1-mediated inflammatory responses in human endothelial cells. Collismycin C also inhibited HMGB1-induced hyperpermeability and leukocyte migration in mice. In addition, collismycin C treatment reduced CLP-induced HMGB1 release and sepsis-related mortality and pulmonary damage in vivo . Our results indicate that collismycin C is a potential therapeutic agent for the treatment of severe vascular inflammatory diseases by inhibiting HMGB1 signaling pathway. Abstract :